HIF1A and neoplasm: In summary, we have developed a bifunctional hypoxia-activated prodrug (CC5) which could make full use of the advantages of the tumor microenvironment to selectively release the cytotoxic agent (CI-944) and HIF-1α inhibitor (YC-1) under hypoxic and acidic conditions.